Company profile
Palatin Technologies, Inc.
NASDAQ: PTN · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 62
v0.1 · 5/100 weight · pillars only
↑ Altman-Z, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$12.9M
Rev growth YoY (TTM)
+3581.2%
Net income (FY)
-$17.3M
Employees
29
as of 2026-09-14
Market cap
$21.2M
as of 2026-09-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$17.3M-$17.3M2025
Operating income-$17.5M-$17.5M2025
Total assets$3.3M$3.3M2025
Liabilities$8.0M$8.0M2025
Equity-$4.8M-$4.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Product Revenue100%
By geography
Not disclosed.
The read
What is Palatin Technologies, Inc.’s revenue?
Palatin Technologies, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
High Sierra Technologies, Inc.——Defence Therapeutics Inc.——Rein Therapeutics Inc.36DEOM Pharmaceuticals Holdings, Inc.——Resverlogix Corp.——Biomind Labs Inc.——Neighbors
Middlesex →Key facts
CEOCarl Spana
SectorHealthcare
IndustryBiotechnology
HeadquartersMonmouth Junction, NJ
ExchangeNASDAQ: PTN
Employees29
IPO date1997-10-15
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.